survivin - Cleveland Clinic

Tag debug info: client: {"assets":{},"datasets":{},"live":{},"projects":{},"users":{},"observable":{"assets":{},"datasets":{},"live":{},"projects":{},"users":{}}}
Now: 1770610779740
Cache Key: cqdTagPageBySlug:survivin
fetchCache[cqdTagPageBySlug:survivin].expirationTime: falsey
fetchCache[cqdTagPageBySlug:survivin]. seconds remaining: falsey
All fetchCache expiration times:
-- Key: cqdNotFoundPage, seconds remaining: 4123
-- Key: cqdTagPageBySlug:facetogenic-pain, seconds remaining: 4123
-- Key: cqdPostsByTag:cqd-migrated-tag-22681,1,10, seconds remaining: 4197
-- Key: cqdTagPageBySlug:device-associated-infections, seconds remaining: 4533
-- Key: cqdPostsByTag:cqd-migrated-tag-26667,1,10, seconds remaining: 4596
-- Key: cqdTagPageBySlug:careen-lowder, seconds remaining: 5899
-- Key: cqdPostsByTag:cqd-migrated-tag-18209,1,10, seconds remaining: 5966
-- Key: cqdTagPageBySlug:prostate-specific-membrane-antigen-psma, seconds remaining: 6516
-- Key: cqdPostsByTag:cqd-migrated-tag-22977,1,10, seconds remaining: 6596
-- Key: cqdTagPageBySlug:wound-care, seconds remaining: 6794
-- Key: cqdPostsByTag:cqd-migrated-tag-329,1,10, seconds remaining: 6855
-- Key: cqdTagPageBySlug:brolucizumab, seconds remaining: 8297
-- Key: cqdPostsByTag:cqd-migrated-tag-26964,1,10, seconds remaining: 8364
-- Key: cqdTagPageBySlug:barlows-disease, seconds remaining: 8599
-- Key: cqdPostsByTag:cqd-migrated-tag-20191,1,10, seconds remaining: 8675
conditions:
-- false,
-- NA,
-- NA,
-- NA
-- false
Cache miss for key cqdTagPageBySlug:survivin - retrieving from Sanity
CCCache.dataFetchCount: 23882
Cache cleanup seconds remaining: 24123

Tag: survivin

Phase II Trial Evaluates Safety of Pembrolizumab plus SurVaxM in Recurrent Glioblastoma

Immunotherapy and Glioblastoma: Assessing Strategies to Harness the Immune System Across a Range of Trials